Boris is adamant to tackle medical needs with chemical solutions. At SumiQ he leads the drug discovery team, aimed at synthesising functionalised compounds, executing biochemical and cellular screening and performing SAR analysis to support hit-to-lead activities.
Boris has worked in (academic) drug discovery ever since receiving his PhD in Bioorganic Chemistry in 2004 from the University of Amsterdam. He started a programme aimed at developing nucleoside analogues as anti-infective agents at the University of Glasgow. In 2005 he moved to the Netherlands Cancer Institute (NKI) and specialised in the Chemical Biology of the ubiquitin-proteasome-antigen presentation triad. In 2008 Boris was appointed Manager/Consultant High-throughput screening supervising academic drug discovery programmes at the NKI. In 2012 Boris moved to Glasgow as a group leader Chemical Biology and Academic Drug Discovery at the Wellcome Trust Centre for Molecular Parasitology. He used chemical genetics, chemical proteomics and functional genomics to validate a deubiquitinating enzyme in the trypanosome parasite as a tractable drug target, which sparked a lead discovery programme in collaboration with Glaxo-Smith-Kline. In 2015 he co-founded UbiQ Therapeutics with Alfred Nijkerk and Farid El Oualid, which lead to the foundation of SumiQ in January 2017.